Chapter 5 - Management of Cytokine Release Syndrome

Abstract

Cytokine release syndrome (CRS) is the most frequently occurring toxicity in patients treated with chimeric antigen receptor T-cell therapies. The definition and grading of CRS has varied over the years. Only recently has the community come to consensus on these topics. However, consensus CRS management guidelines do not exist owing to the incredibly complex and variable nature of CRS across products and patient populations. This chapter will summarize the historical and current standard approaches to CRS grading then provide a framework and discussion of key points in the management of CRS focusing on supportive care by organ systems and optimal timing of intervention with anti-cytokine therapies.